Incannex shares jumped nearly 15% after the FDA granted Fast Track status to IHL-42X, its oral therapy for obstructive sleep apnea. The designation, supported by strong Phase 2 results, offers benefits like rolling review and increased FDA interaction. Retail sentiment highlighted the significant unmet need and long-term optimism for the treatment.